24.10.2014 • News

Vetter Announces Personnel Changes in its Development Service Division

Dr. Susanne Resatz has been appointed as President of Vetters clinical...
Dr. Susanne Resatz has been appointed as President of Vetter's clinical development facility in Chicago, Illinois.

Dr. Susanne Resatz, formerly Manager Process Development and Manufacturing at Vetter's clinical development facility in Chicago, Illinois, has assumed the role of President. Resatz will be fully responsible for the site's operations. Dr. Claudia Roth, who held this position before, will repatriate to the company headquarters in Ravensburg, Germany where she will head up the newly created "Innovation" department. Both Resatz and Roth have been with Vetter's US facility since its opening in 2009, and were instrumental in its early construction through to its becoming fully operational in October 2011. Resatz's expertise includes designing and implementing highly efficient, high-quality manufacturing processes for early-stage products. She holds a PhD in biomedical engineering from the Vienna University of Technology.

Vetter also announced that Dr. Paul Nelles, who headed Vetter´s global Development Service activities, will take early retirement after 11 years of service with Vetter. His replacement, Dr. Claus Feussner, formerly vice president Quality Control, has assumed the title of senior vice President of Vetter Development Service effective September 1. Nelles will continue with his efforts at Vetter until mid-2015 to help with the transition.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read